Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Business Officer | August 10, 2021 | August 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date August 10, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,330 |
Ending reported balance
After 2021-08-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-08-10 · Exercise / conversion · Acquired 7,500 · Balance 11,830 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2021-08-10 · Sale · Disposed 5,620 · Balance 6,210 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 3 · 2021-08-10 · Sale · Disposed 1,880 · Balance 4,330 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2027-02-01 | Direct | 6,562 |
Reported balance
After 2021-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-10 · Exercise / conversion · Disposed 7,500 · Balance 6,562 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5: The option is fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 116,666 |
Reported balance
Holding disclosure · report date 2021-08-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 116,666 F4: The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34.
F4: The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2021 Filed Aug 11, 2021 18:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-050976 · doc4.xml · derivative · entry 5 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,562 Underlying: Common Stock · 7,500 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 18:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,880 | $30.21 | $56,797.24 |
DisclosureSEC source: 0001209191-21-050976 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 18:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,620 | $29.74 | $167,128.68 |
DisclosureSEC source: 0001209191-21-050976 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 18:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 7,500 | $1.11 | $8,325.00 |
DisclosureSEC source: 0001209191-21-050976 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| July 12, 2021 Filed Jul 12, 2021 19:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-046362 · doc4.xml · derivative · entry 5 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,062 Underlying: Common Stock · 7,500 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| July 12, 2021 Filed Jul 12, 2021 19:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $24.73 | $9,892.00 |
DisclosureSEC source: 0001209191-21-046362 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $24.65 and the highest price at which shares were sold was $24.79. Read SEC document |
| July 12, 2021 Filed Jul 12, 2021 19:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 7,100 | $23.88 | $169,526.70 |
DisclosureSEC source: 0001209191-21-046362 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,730 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.62 and the highest price at which shares were sold was $24.40. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| July 12, 2021 Filed Jul 12, 2021 19:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 7,500 | $1.11 | $8,325.00 |
DisclosureSEC source: 0001209191-21-046362 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039810 · doc4.xml · derivative · entry 6 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,562 Underlying: Common Stock · 7,500 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $30.90 | $12,361.48 |
DisclosureSEC source: 0001209191-21-039810 · doc4.xml · nonDerivative · entry 4 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,100 | $30.01 | $33,005.61 |
DisclosureSEC source: 0001209191-21-039810 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,730 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 6,000 | $29.15 | $174,881.40 |
DisclosureSEC source: 0001209191-21-039810 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,830 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 7,500 | $1.11 | $8,325.00 |
DisclosureSEC source: 0001209191-21-039810 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 10, 2021 Filed May 11, 2021 19:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-031891 · doc4.xml · derivative · entry 6 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,062 Underlying: Common Stock · 7,500 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 10, 2021 Filed May 11, 2021 19:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 700 | $27.66 | $19,363.47 |
DisclosureSEC source: 0001209191-21-031891 · doc4.xml · nonDerivative · entry 4 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.42 and the highest price at which shares were sold was $27.95. Read SEC document |
| May 10, 2021 Filed May 11, 2021 19:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,501 | $26.87 | $67,213.12 |
DisclosureSEC source: 0001209191-21-031891 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $26.41 and the highest price at which shares were sold was $27.32. Read SEC document |
| May 10, 2021 Filed May 11, 2021 19:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,299 | $26.07 | $112,067.62 |
DisclosureSEC source: 0001209191-21-031891 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,531 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.40 and the highest price at which shares were sold was $26.39. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| May 10, 2021 Filed May 11, 2021 19:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 7,500 | $1.11 | $8,325.00 |
DisclosureSEC source: 0001209191-21-031891 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,104 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · derivative · entry 8 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,562 Underlying: Common Stock · 5,104 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,396 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · derivative · entry 7 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,396 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 545 | $28.65 | $15,616.92 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · nonDerivative · entry 5 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $28.32 and the highest price at which shares were sold was $29.25. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,883 | $27.67 | $79,769.73 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · nonDerivative · entry 4 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.27 and the highest price at which shares were sold was $28.18. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,072 | $26.83 | $109,245.24 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $26.25 and the highest price at which shares were sold was $27.24. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,104 | $1.11 | $5,665.44 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,396 | $0.84 | $2,012.64 |
DisclosureSEC source: 0001209191-21-026457 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 19:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,330 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-023086 · doc4.xml · derivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396 Underlying: Common Stock · 4,330 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 25, 2021 Filed Mar 25, 2021 19:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 4,330 | $0.84 | $3,637.20 |
DisclosureSEC source: 0001209191-21-023086 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 16:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-018935 · doc4.xml · derivative · entry 6 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,726 Underlying: Common Stock · 7,500 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 16:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 200 | $38.34 | $7,668.00 |
DisclosureSEC source: 0001209191-21-018935 · doc4.xml · nonDerivative · entry 4 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.23 and the highest price at which shares were sold was $38.45. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 16:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,490 | $37.31 | $167,503.94 |
DisclosureSEC source: 0001209191-21-018935 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.94 and the highest price at which shares were sold was $37.63. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 16:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,810 | $36.48 | $102,506.55 |
DisclosureSEC source: 0001209191-21-018935 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.93 and the highest price at which shares were sold was $36.91. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 16:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 7,500 | $0.84 | $6,300.00 |
DisclosureSEC source: 0001209191-21-018935 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,096 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · derivative · entry 11 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,678 Underlying: Common Stock · 2,096 shares Expires 2030-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F9 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning June 28, 2020 until the option is fully vested on May 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,797 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · derivative · entry 10 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,869 Underlying: Common Stock · 3,797 shares Expires 2030-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F8 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,107 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · derivative · entry 9 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,226 Underlying: Common Stock · 9,107 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F7 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $37.88 | $15,150.00 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 8 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.74 and the highest price at which shares were sold was $38.01. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,000 | $36.92 | $36,924.00 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 7 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.58 and the highest price at which shares were sold was $37.30. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 6,400 | $35.99 | $230,328.32 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 6 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.53 and the highest price at which shares were sold was $36.50. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,553 | $35.02 | $159,453.80 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 5 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $34.52 and the highest price at which shares were sold was $35.50. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,647 | $34.19 | $90,495.64 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 4 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,353 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $33.51 and the highest price at which shares were sold was $34.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,096 | $9.57 | $20,058.72 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 3 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,797 | $7.26 | $27,566.22 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 2 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 16:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 9,107 | $0.84 | $7,649.88 |
DisclosureSEC source: 0001209191-21-012661 · doc4.xml · nonDerivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 19:21 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $38.97 | $0.00 |
DisclosureSEC source: 0001209191-21-010437 · doc4.xml · derivative · entry 1 Beaurang Pierre · CIK 0001817226 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning March 11, 2021 until the option is fully vested on February 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.